USMCA Countdown, Oil Optimism, and Q3 Opens

The last time conditions loosely resembled this Wednesday morning was Q4 2018, when the Fed was tightening into softening data, trade war escalation was rattling markets, and geopolitical headlines from the Middle East kept energy prices volatile. Back then, the S&P 500 dropped 20% in a quarter before reversing sharply once the Fed pivoted, among other factors including a trade truce with China. The parallel is loose, but the ingredients are familiar: a major trade agreement now has a countdown clock, oil is pricing in geopolitical optimism that hasn't fully materialized, and tech is leading a rotation into the new quarter. The difference today is that markets are entering Q3 on the front foot rather than on the back foot, with the S&P 500 closing the prior session up 0.79% and the Nasdaq gaining 1.52%.

A quick note before we dig in: everything below is observational research from the agent's output, not personalized guidance. If anything here sparks an idea, please talk to an authorized financial advisor before acting on it.

The Two Headlines That Frame Q3

Two stories this morning set the stage for the quarter ahead.

First, the US is reportedly not planning to extend USMCA, the trade agreement governing commerce between the US, Mexico, and Canada. This effectively starts a decade-long countdown to the pact's expiration. That might sound distant, but markets tend to front-run structural trade shifts well before deadlines arrive. The Mexican IPC index fell 1.0% in the prior session, and the Mexico ETF (EWW) was already down 1.12%. For research subjects with North American supply chain exposure, this is a slow-building headwind worth watching.

Second, US and Iranian officials are meeting with mediators in Qatar. This is happening days after a new round of attacks threatened efforts to sign a lasting peace deal. As I discussed in US Iran Deal and Market Rotation: Week Ahead, the Iran diplomacy track has been a dominant force shaping energy prices and risk appetite for weeks. Oil prices ended Q2 with a steep quarterly decline on optimism about a deal. But as a headline this morning puts it, that optimism at the Strait of Hormuz has "yet to justify" itself. The energy sector sold off in the prior session, reflecting the market's bet that more supply is coming even though the deal isn't signed.

Russia, China, and AI: The Quieter Signals

A couple of other headlines deserve attention. Reports that Russia approved secret military training cooperation with China at the highest levels adds another layer to the geopolitical picture. This doesn't move markets directly today, but it shapes the medium-term risk environment for anything tied to defense spending, supply chains, and sanctions policy.

Meanwhile, the AI investment thesis got a major data point: Abu Dhabi's MGX raised $49 billion for one of the biggest AI funds ever assembled. That figure underscores how seriously sovereign capital is treating AI as a structural theme, not a cyclical trade. Separately, China is reportedly thinking hard about how to keep humans employed as it embeds AI across every industry. And Anthropic announced the US lifted an export ban on its advanced AI tools, which had been suspended in June over hacking concerns. The lifting of that ban is a modest tailwind for the AI ecosystem and suggests the regulatory pendulum may have swung back slightly toward openness.

Tech Leads, Defensives Lag: A Clean Sector Rotation

Looking at the numbers from the prior session, the rotation pattern is striking. The tech-heavy Nasdaq gained 1.52%, and the Netherlands ETF (EWN) gained 1.82%, likely reflecting ASML and the semiconductor supply chain. The S&P 500 Information Technology sector index (^SP500-45) fell 1.05%, which may reflect compositional differences with broader tech ETFs, but the QQQ's 1.70% gain and the Nasdaq's outperformance tell the clearer story: growth led the session.

On the defensive side, the consumer staples and healthcare sectors lagged the broader market, consistent with a risk-on rotation where money moves out of defensive sectors and into growth. This is textbook behavior for a market entering a new quarter with momentum.

The VIX fell 6.8% to 16.45, which is well within the calm range. Bond markets were mixed, with the 10-year yield slipping slightly to 4.372% while the 30-year edged up to 4.864%. That mild steepening at the long end is worth noting for rate-sensitive subjects.

All 11 Research Subjects: Where Things Stand

Let me walk through every subject the agent is currently studying, connecting each to today's environment.

CRM (Salesforce) is sitting at $156.66, down 1.08% from the agent's research entry. The broader tech rally in the prior session should provide a constructive backdrop. The thesis here rests on extreme valuation dislocation for a profitable enterprise software company, and the Anthropic export ban being lifted is a small but positive signal for the AI tools ecosystem that Salesforce is embedding into its Agentforce platform. The MGX $49 billion AI fund also reinforces the structural demand case for enterprise AI infrastructure. No thesis review has been logged yet, so the agent is still building its initial observation window.

Samsung Electronics (005930.KS) is at 316,000 KRW, down 2.17% from entry. South Korea's KOSPI fell 2.04% in the prior session, the worst performer among major Asian indexes. That's a notable divergence from the global risk-on mood. Interestingly, the South Korea ETF (EWY) gained 2.23%, suggesting the weakness may be more about local dynamics than global sentiment. The thesis centers on extreme valuation in memory semiconductors, and the agent learned from the Micron experience (more below) that semiconductor re-entries at elevated prices are risky. Samsung's entry was fresh, not a re-entry, which is a meaningful distinction.

META (Meta Platforms) is at $563.29, up 2.37% from the current research entry. Worth noting that the agent had a prior META entry that was closed last week at a negative 5.19% observed delta after compounding losses across multiple reviews. The agent re-entered at a lower price ($550.25 versus $593.00), which is the right application of the lesson about not chasing elevated re-entries. The tech-led rally and AI sentiment improvement from both the Anthropic news and the MGX fund are constructive for this thesis.

PepsiCo (PEP) sits at $135.40, down 4.24% from entry, making it one of the weaker active subjects. Consumer staples lagged in the prior session, and the risk-on rotation away from defensives is the exact opposite of what this thesis needs. The agent hasn't published a thesis review yet. I'll be honest: a 4.24% drawdown in a low-risk, defensive name is uncomfortable, especially given the research history showing that value-oriented defensive theses have a mixed track record.

Gilead Sciences (GILD) is at $126.34, up 2.08%, with a healthy thesis status (5/5). Healthcare broadly lagged in the prior session, but GILD's thesis is built on hypergrowth characteristics, not defensive positioning. As the agent's research learnings show, the only healthcare wins have come from genuine growth catalysts, and GILD's 54.8% earnings growth at entry qualifies. The thesis continues to hold.

Visa (V) is the strongest active subject at $343.09, up 4.84% from entry, also with a healthy thesis (5/5). Financials were flat to slightly down in the prior session, but Visa operates as a network model with low credit sensitivity, so it behaves more like a quality compounder than a traditional bank stock. The pattern the thesis anticipated, digital payments leadership providing defensive growth, is playing out.

Adobe (ADBE) is at $205.02, up 0.49% from entry, with a healthy thesis (5/5). The prior session's tech rally is constructive, and ADBE's thesis is built on a nearly 50% decline from highs creating an extreme dislocation. At a confidence of 70%, this is the agent's highest-conviction active subject. The AI tools ecosystem developments, including the Anthropic ban being lifted, may gradually ease the market's fears about AI disruption to creative software.

Eli Lilly (LLY) is at $1,199.43, up 5.86% from entry, thesis intact (5/5). Despite the broader healthcare sector weakness, LLY's GLP-1 franchise makes it fundamentally different from the sector. This confirms a pattern the agent has observed: healthcare names with genuine hypergrowth catalysts behave independently from sector-level weakness. The thesis is in good shape.

Procter & Gamble (PG) is essentially flat at $146.64, up just 0.07% from entry, thesis intact (5/5). As flagged in Week Review: Asia Selloff, Iran Strikes, Rotation, PG had been demonstrating defensive relative strength in recent weeks. The prior session's risk-on rotation worked against it, as consumer staples broadly underperformed. At 54% confidence, this is the agent's lowest-conviction subject among the thesis-intact group. Worth watching to see if the defensive bid returns.

XLF (Financial Select Sector ETF) closed at $53.61, up 2.5% from entry, thesis intact (5/5). Financials were flat in the prior session, slightly giving back ground. Notably, a headline this morning highlights Europe's bank bulls seeing more upside after a 21% quarterly gain, which suggests the financials rotation may have broader global support. With a 3-month horizon and 52% confidence, this sits in the zone where the agent's research history suggests caution. Positions with 3-month horizons and sub-55% confidence have historically underperformed. The yield curve dynamics that support the thesis, with a positive 10Y-2Y spread, remain in place.

IWM (Russell 2000 ETF) is at $300.45, up 5.38% from entry, but carries a minor-concerns health flag (4/5) and just 33% confidence. The agent is watching this subject closely. Small caps gained 0.50% via IWM in the prior session (the Russell 2000 index itself rose 0.46%), underperforming the S&P 500's 0.79% gain. That underperformance doesn't support the rotation thesis. At 33% confidence, this is deep in the territory where research history says losses are likely. The system is monitoring and will close this if the thesis breaks further.

Lessons From Last Week's Closures

The agent closed four research subjects recently, and the pattern is instructive. Micron (MU) hit its stop-loss at negative 7.25%, confirming the lesson about semiconductor re-entries at elevated prices. The Japan ETF (EWJ) was closed at negative 3.65% via the confidence gate, and MSFT was closed at negative 6.47% through the same mechanism. The prior META entry was closed at negative 5.19% after compounding losses across reviews.

Three of these four exits were triggered by the confidence gate, the system that closes a subject when confidence drops below 0.65 and the drawdown exceeds 3%. The agent learned from these misses that the confidence scoring function genuinely works as a filter. The challenge is applying that discipline at the point of entry, not just at exit.

What the Agent Is Watching Next

Q3 opened with a clean risk-on signal: tech leading, defensives lagging, VIX dropping, and bond yields relatively stable. The USMCA countdown introduces a new structural variable for North American-exposed names. And the Qatar talks between the US and Iran are the near-term event that could either validate or invalidate the oil market's optimism.

From what I'm seeing, the biggest question for this quarter is whether the tech leadership broadens or narrows. The Nasdaq's 1.52% gain compared to the Dow's 0.26% is a wide gap. If that continues, it favors subjects like ADBE, META, and CRM while putting pressure on the defensive names like PEP and PG. If it reverses, the opposite holds.

I'll be watching how Samsung navigates the KOSPI weakness, whether IWM's thesis holds up under its low-confidence flag, and whether the Iran talks produce something concrete enough to justify where oil is priced.

Research output, not investment advice. The material above is observational and educational. The operator of Observed Markets may hold personal positions in subjects the agent studies (disclosed at observedmarkets.com/conflicts-of-interest). Always consult an authorized financial advisor before any investment decision. Past observed outcomes do not predict future results.